Exelixis News

SOUTH SAN FRANCISCO, Calif. -- -- Exelixis, Inc. today announced the initiation of COMET-1, a phase 3 pivotal trial of cabozantinib in men with metastatic castration-resistant prostate cancer .

SOUTH SAN FRANCISCO, Calif. -- -- Exelixis, Inc. today announced that it has completed the filing of its rolling New Drug Application with the U.S. Food and Drug Administration for cabozantinib as a treatment for patients with progressive, unresectable, locally advanced, or metastatic medullary thyroid cancer .

SOUTH SAN FRANCISCO, Calif. -- -- Exelixis, Inc. reiterated its slate of activities in conjunction with the 2012 American Society of Clinical Oncology Annual Meeting, which will be held June 1-5, 2012, in Chicago, Illinois.

SOUTH SAN FRANCISCO, Calif. -- -- Exelixis, Inc. announced today that Michael M. Morrissey, Ph.D., the company's president and chief executive officer, will present at the Bank of America Merrill Lynch 2012 Health Care Conference at 3:00 p.m. EDT / noon PDT on Thursday, May 17, 2012, in Las Vegas.

Volatile biotech Dendreon has been a painful lesson for some investors that there's a big difference between good technology and a good stock.

Good day, Ladies and Gentlemen, and welcome to the First Quarter 2012 Exelixis' Financial Results Conference Call.

SOUTH SAN FRANCISCO, Calif. -- -- Exelixis, Inc. today announced a broad expansion of the cabozantinib development program under a Cooperative Research and Development Agreement with the National Cancer Institute's Cancer Therapy Evaluation Program , with the approval of the initial program of 12 proposed clinical trials under the agreement.

SOUTH SAN FRANCISCO, Calif. -- -- Exelixis, Inc. announced today that Frank Karbe, the company's executive vice president and chief financial officer, will present at the upcoming Deutsche Bank Securities 37th Annual Health Care Conference at 4:50 p.m. EDT / 1:50 p.m. PDT on Tuesday, May 8, 2012, in Boston.